No­vo helps birth start­up ad­vanc­ing an As­traZeneca castoff with $15M; Japan's Fu­ji Phar­ma wa­gers $50M on Alvotech's ...

7 years ago
News Briefing

No­var­tis CAR-T chief drops out of Big Phar­ma, joins the great mi­gra­tion to a fa­vorite biotech des­ti­na­tion

7 years ago
People

Tar­get­ing un­der­ly­ing cause of PAH, Cam­bridge spin­out Mor­phogen-IX rais­es about $23M in Se­ries B

7 years ago
Financing
Startups

En­tra­da launch­es to­day, tak­ing a $59M shot at some tough in­tra­cel­lu­lar tar­gets

7 years ago
Financing
Startups

Jonathan Lim is­n't ready to say much about his new start­up, but he does have $42M for it

7 years ago
Financing
Startups

Sec­ond dose of Sophiris' prostate can­cer drug proves fu­tile, shares crash

7 years ago
R&D

Sanofi is con­cen­trat­ing its forces in Cam­bridge hub, ink­ing a mas­sive lease for 2,700 staffers

7 years ago
Pharma

Fi­bro­Gen, As­traZeneca score Chi­na ap­proval for ane­mia drug ahead of piv­otal US da­ta

7 years ago
China
Pharma

FDA names new No. 2 to re­place re­tir­ing Sher­man

7 years ago
Pharma

Ver­tex CFO Thomas Graney ex­its abrupt­ly; Eli Lil­ly touts a head-to-head win over Hu­mi­ra

7 years ago
News Briefing

Jun­shi wins the race for first made-in-Chi­na PD-1 ap­proval as ex­ecs reap $394M IPO har­vest

7 years ago
Financing
China

No­vo Nordisk grabs a $486M buy­out op­tion on an an­ti-apoC3 an­ti­body for its car­dio R&D group

7 years ago
Deals
Pharma

Tossed in a storm of con­tro­ver­sies, Pro­teosta­sis finds shel­ter in $100M cash Roche deal — shares surge

7 years ago
Pharma

Ver­sant part­ners gear up for a $700M bo­nan­za of biotech bets, with a spe­cial fo­cus all their own

7 years ago
Financing

Broad­en­ing its on­col­o­gy fo­cus, In­novent adds three In­cyte drugs to port­fo­lio for $40M cash

7 years ago
R&D
China

Har­vard prof Omid Farokhzad heads west, set­ting up a new Bay Area biotech on a mis­sion to start a rev­o­lu­tion in ...

7 years ago
Financing
Startups

Eu­ro­pean VC firm Kur­ma sets its sights on €150 mil­lion fund, its biggest ever

7 years ago
Financing

Tesaro ex­ecs split $304M wind­fall from $5.1B Glax­o­SmithK­line buy­out

7 years ago
People
Deals

Eli Lil­ly has an­ted up for its next big bet on a next-gen pain drug, buy­ing Hy­dra as­sets

7 years ago
Pharma

Anato­my of a long-de­layed biotech buy­out: With its stock price beat­en down, aban­doned by po­ten­tial bid­ders, Tesaro ...

7 years ago
Pharma

Soft­ware de­vel­op­er Syn­thace rais­es $25.6M to re­al­ize 'com­put­er aid­ed bi­ol­o­gy'

7 years ago
Financing
AI

Shinichi Tamu­ra re­claims the throne at So­sei; Jeff Abbey ex­its Ar­gos for No­vadip; Frank Cz­er­wiec is the new CMO at ...

7 years ago
Peer Review

Plow­ing ahead af­ter its lat­est set­back, Ax­o­vant nabs two as­sets to beef up gene ther­a­py pipeline

7 years ago
R&D
Pharma

As­traZeneca wants a do-over on MYS­TIC com­bo da­ta. But a change­up in fo­cus won’t end the death watch on this pair­ing

7 years ago
Bioregnum
R&D
First page Previous page 973974975976977978979 Next page Last page
A service from the Financial Times